<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04101370</url>
  </required_header>
  <id_info>
    <org_study_id>BOZ-501</org_study_id>
    <nct_id>NCT04101370</nct_id>
  </id_info>
  <brief_title>Bioequivalence Study of Bosentan 125 mg Tablets Immediate Release (IR) Versus Tracleer® 125 mg Tablets IR In Healthy Subjects</brief_title>
  <official_title>Two-way Crossover, Open-label, Single-dose, Bioequivalence Study of Bosentan (LLC &quot;GEROPHARM&quot;, Russia) 125 mg Tablets Immediate Release (IR )Versus Tracleer® (Actelion Pharmaceuticals Ltd., Switzerland) 125 mg Tablets IR in Normal Healthy Subjects Under Fasting Conditions</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Geropharm</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Geropharm</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      Bioequivalence Study of 2 formulation of bosentan (Bosentan GEROPHARM vers. Tracleer®&#xD;
      Actelion)&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Study to evaluate the bioequivalence of orally administered bosentan preparations, immediate&#xD;
      release tablets, 125 mg in normal healthy subjects under fasting conditions&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">May 24, 2018</start_date>
  <completion_date type="Actual">June 20, 2018</completion_date>
  <primary_completion_date type="Actual">June 20, 2018</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <intervention_model_description>Crossover Assignment two-way crossover</intervention_model_description>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>None (Open Label)</masking>
    <masking_description>Open Label</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>Cmax</measure>
    <time_frame>0 hours (pre-dose), as well as at 0.5, 1, 1.5, 2, 2.5, 3, 3,5, 3,75, 4, 4.25, 4.5, 4.75, 5, 6, 8, 10, 12, 14 and 24 hour post-dose.</time_frame>
    <description>Pharmacokinetics of bosentan by Assessment of Observed Maximum Plasma Concentration (Cmax)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>AUC(0-t)</measure>
    <time_frame>0 hours (pre-dose), as well as at 0.5, 1, 1.5, 2, 2.5, 3, 3,5, 3,75, 4, 4.25, 4.5, 4.75, 5, 6, 8, 10, 12, 14 and 24 hour post-dose.</time_frame>
    <description>Pharmacokinetics of bosentan by Assessment of Area Under the Curve From Time Zero Extrapolated to &quot;t&quot; (AUC(0-t))</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">64</enrollment>
  <condition>Bioequivalence</condition>
  <arm_group>
    <arm_group_label>Bosentan</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Single administered dose of Bosentan (125 mg tablet immediate release) in a fasting condition</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Tracleer®</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Single administered dose of Tracleer® (125 mg tablet immediate release) in a fasting condition</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Bosentan 125 mg</intervention_name>
    <description>Single administered dose of Bosentan (125 mg tablet immediate release) in a fasting condition</description>
    <arm_group_label>Bosentan</arm_group_label>
    <other_name>bosentan</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Tracleer 125Mg Tablet</intervention_name>
    <description>Single administered dose of Tracleer® (125 mg tablet immediate release) in a fasting condition</description>
    <arm_group_label>Tracleer®</arm_group_label>
    <other_name>bosentan</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Signed informed consent form.&#xD;
&#xD;
          -  Healthy male aged 18 to 45 years.&#xD;
&#xD;
          -  Verified diagnosis is &quot;healthy&quot; according to data Standard clinical, laboratory and&#xD;
             Instrumental methods of examination.&#xD;
&#xD;
          -  Have a body mass index between 18,5 and 30 kg/m2.&#xD;
&#xD;
          -  Subjects must use, with their partner, methods of highly effective contraception&#xD;
             throughout the study and 30 days after the end of study.&#xD;
&#xD;
          -  Ability to keep fasting state for at least 14 hours.&#xD;
&#xD;
          -  Consent and ability to respect the schedule of visits and the points of the Protocol.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  History of serious allergic problems/events.&#xD;
&#xD;
          -  Medicinal intolerance.&#xD;
&#xD;
          -  Any acute and chronic diseases of the cardiovascular system, cardiovascular,&#xD;
             bronchopulmonary, neuroendocrine systems, as well as diseases of the gastrointestinal&#xD;
             tract, liver, kidneys, blood.&#xD;
&#xD;
          -  Psychiatric disorders, history of epilepsy and seizures.&#xD;
&#xD;
          -  Acute infectious diseases in less than 4 weeks before the start of the study.&#xD;
&#xD;
          -  Subjects who have taken medication 2 weeks preceding before the study.&#xD;
&#xD;
          -  Subjects who have taken any drugs known effects on hemodynamics or to induce or&#xD;
             inhibit hepatic drug metabolism within 30 days prior to administration of the study&#xD;
             medication (examples of inducers: barbiturates, omeprazole, etc.).&#xD;
&#xD;
          -  Donation of plasma (450 mL or more) within 2 month prior to administration of the&#xD;
             study medication.&#xD;
&#xD;
          -  History of significant alcohol or drugs abuse or any indication of the regular use of&#xD;
             more than 10 units of alcohol per week (1 Unit = 200 mL of wine or 500 mL of beer or&#xD;
             50 mL of alcohol 40%).&#xD;
&#xD;
          -  Smokers.&#xD;
&#xD;
          -  Participation in other clinical training is less than than for 3 months before the&#xD;
             study.&#xD;
&#xD;
          -  Lack of signed informed consent form.&#xD;
&#xD;
          -  10% deviation from references in lab tests.&#xD;
&#xD;
          -  Positive testing for alcohol, drugs.&#xD;
&#xD;
          -  Dehydration due to diarrhea, vomiting, or other causes within the last 24 hours before&#xD;
             the start of the study.&#xD;
&#xD;
          -  Any diet (vegetarian, etc.) extreme physical exercise, night shift work.&#xD;
&#xD;
          -  Heart rate below 60 or above 80 beats per minute.&#xD;
&#xD;
          -  Systolic blood pressure less than 110 mm Hg or more than 139 mm Hg.&#xD;
&#xD;
          -  Diastolic blood pressure less than 60 mm Hg or more than 89 mm Hg.&#xD;
&#xD;
          -  Volunteers, for Investigator opinion, who can not understand and evaluate the&#xD;
             information about this study.&#xD;
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>45 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Clinical Hospital № 3</name>
      <address>
        <city>Yaroslavl</city>
        <zip>150007</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Russian Federation</country>
  </location_countries>
  <verification_date>March 2019</verification_date>
  <study_first_submitted>September 23, 2019</study_first_submitted>
  <study_first_submitted_qc>September 23, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">September 24, 2019</study_first_posted>
  <last_update_submitted>September 23, 2019</last_update_submitted>
  <last_update_submitted_qc>September 23, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">September 24, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>AUC</keyword>
  <keyword>Cmax</keyword>
  <keyword>Pharmacokinetics</keyword>
  <keyword>bosentan</keyword>
  <keyword>fasting</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Bosentan</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

